Showing results (201-210 of 322) with videos related to

Sort By:
Pageof 33
Haematologica|June 13, 2015
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosisAlessandro M Vannucchi, Hagop M Kantarjian, Jean-Jacques Kiladjian, et al.
The Journal of Experimental Medicine|July 13, 2016
Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosisTakafumi Shimizu, Lucia Kubovcakova, Ronny Nienhold, et al.
Haematologica|September 23, 2021
Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopeniaSrdan Verstovsek, Ruben Mesa, Moshe Talpaz, et al.
Hemasphere|May 10, 2021
Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA TrialRuben A Mesa, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Blood|August 23, 2007
JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosisGiovanni Barosi, Gaetano Bergamaschi, Monia Marchetti, et al.
Drug Design, Development and Therapy|June 2, 2015
Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating studyNicola Cascavilla, Valerio De Stefano, Fabrizio Pane, et al.
Frontiers in Oncology|May 14, 2023
Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma NetworkElisabetta Antonioli, Sofia Pilerci, Irene Attucci, et al.
British Journal of Haematology|January 17, 2020
Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia veraAyalew Tefferi, Paola Guglielmelli, Terra L Lasho, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|July 21, 2024
Real-World Efficacy and Safety of Plasma-Derived Von Willebrand Factor-Containing Factor VIII Concentrates in Patients With Von Willebrand Disease in ItalyAugusto B Federici, Rita Carlotta Santoro, Cristina Santoro, et al.
British Journal of Haematology|November 19, 2016
The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF)Ruben Mesa, Alessandro M Vannucchi, Abdulraheem Yacoub, et al.
Pageof 33